Navigation Links
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
Date:11/3/2008

SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific Sessions 2008 in New Orleans.

John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, will present the data from the multicenter, international Pre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy to Presentation" that will focus on new approaches to the treatment of acute heart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST on Monday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.

According to the AHA, heart failure is a costly syndrome contributing to more than 3 million hospitalizations each year in the U.S. The great majority of patients with acute heart failure have fluid accumulation in the lungs (congestion) that causes shortness of breath and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women. Data from a pilot study in patients with heart failure support the expectation that these effects may be beneficial in relieving the signs and symptoms of heart failure.

About Corthera

Corthera Inc. is a biopharmaceutical company committed to acquiring, developing a
'/>"/>

SOURCE Corthera
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
2. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
3. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
9. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
10. Symmetry Medical Reports Preliminary Third Quarter Revenue
11. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 27, 2015 , ... Capital Edge Consulting , a nationwide consulting firm ... announce their ranking as one of the top 5000 companies listed on the ... the nation. , “It is truly an honor to be recognized as one of ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... , Aug. 27, 2015 In ... by FedEx, UPS and The US Postal Service ... specimens classified as ,select agents, by the CDC, ... of handling these sensitive shipments. Marken ... transportation regulations, trained and certified personnel to ensure ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a ... development and manufacture of highly valued cardiac markers used in early detection of ... with protein chemistry has led to the development and commercialization of important cardiac ...
Breaking Biology Technology:Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... SilOnIS shared the 2007 Jean-Pierre Noblanc ... sustainable project in the EUREKA MEDEA+,microelectronics Cluster. ... and mobile multimedia applications that makes life ... value for network operators. SilOnIS combines strained ...
... for Women Seeking Relief of ... Menopausal Symptoms, ... Initiative (WHI) study published,today in the Journal of the American Medical ... therapy when it is,prescribed to symptomatic, newly menopausal women. Wyeth Pharmaceuticals, ...
... The Board of Directors of,Bristol-Myers Squibb Company (NYSE: ... per share on the $.10 par value Common,Stock of the ... to stockholders of record at the close of business on ... dividend of fifty cents ($0.50),per share on the $2.00 Convertible ...
Cached Biology Technology:MEDEA+ Noblanc award highlights improvements in microelectronics 2MEDEA+ Noblanc award highlights improvements in microelectronics 3WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 2WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 3WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy 4
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/24/2015)... 24, 2015  Based on its recent analysis of the ... 2015 African Biometrics Company of the Year Award. DERMALOG is ... success in Africa . It has particularly ... has implemented one of the largest biometric mass applications in ... the Central Bank of Nigeria with ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... Boston have developed a new nanobiotechnology that enables ... They describe the technology, which could lead to ... January issue of Nature Nanotechnology (published online January ... Mannix, PhD, of Childrens program in Vascular Biology, ...
... transcription -- the intricate transfer of information from a ... RNA -- isn,t stationed in special "transcription factories" within ... enzyme RNA polymerase II (Pol II) and other key ... gene, regardless of the gene,s position., The findings, published ...
... for Biomolecular Sciences (SBS) WHAT: Latest Findings and ... WHEN: April 6-10, 2008 WHERE: SBS ... BACKGROUND: More than 2,500 researchers and professionals ... expected to attend the 14th Annual Conference & Exhibition of ...
Cached Biology News:An 'attractive' man-machine interface 2An 'attractive' man-machine interface 3Research sheds light on the mechanics of gene transcription 2